Clinical Trial Update: Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial of VVN461 Ophthalmic Solution for post-operative ocular inflammation after cataract surgery has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Inflammation

Drugs mentioned

• VVN461 ophthalmic solution (VVN461)

Snippet

Sponsor: VivaVision Biotech, Inc | Conditions: Inflammation | Phase 2 | Status: COMPLETED | Results posted: 2025-06-10